Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:RXRX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeRXRXRecursion Pharmaceuticals$5.81-2.7%$7.44$5.60▼$12.36$2.34B0.8510.75 million shs15.13 million shs7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceRXRXRecursion Pharmaceuticals-2.68%-13.02%-30.34%-21.38%-42.87%Remove AdsCompare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationRXRXRecursion Pharmaceuticals2.1724 of 5 stars3.22.00.00.02.22.50.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceRXRXRecursion Pharmaceuticals 2.40Hold$8.2542.00% UpsideCurrent Analyst Ratings BreakdownLatest RXRX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails2/28/2025RXRXRecursion PharmaceuticalsCowenSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingHold ➝ Hold2/28/2025RXRXRecursion PharmaceuticalsLeerink PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetMarket Perform ➝ Market Perform$7.00 ➝ $6.002/6/2025RXRXRecursion PharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$11.00 ➝ $11.001/8/2025RXRXRecursion PharmaceuticalsKeyCorpSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$12.00 ➝ $10.00(Data available from 3/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookRXRXRecursion Pharmaceuticals$58.49M39.93N/AN/A$1.98 per share2.93Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateRXRXRecursion Pharmaceuticals-$328.07M-$1.66N/AN/AN/A-579.52%-76.56%-55.68%5/8/2025 (Estimated)Latest RXRX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails2/28/2025Q4 2024RXRXRecursion Pharmaceuticals-$0.36-$0.53-$0.17-$0.53$19.04 million$4.60 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthRXRXRecursion PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioRXRXRecursion Pharmaceuticals0.044.354.35Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipRXRXRecursion Pharmaceuticals89.06%Insider OwnershipCompanyInsider OwnershipRXRXRecursion Pharmaceuticals15.75%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableRXRXRecursion Pharmaceuticals400401.99 million329.18 millionOptionableRXRX HeadlinesRecent News About These CompaniesHighTower Advisors LLC Acquires 98,626 Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)March 28 at 3:22 AM | marketbeat.comRecursion: A Look At Near-Term Phase 1b And Phase 2 CatalystsMarch 27 at 11:30 AM | seekingalpha.comSwiss National Bank Grows Stock Position in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)March 27 at 3:29 AM | marketbeat.comIs Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) the Best AI Stock to Invest in According to Reddit?March 26 at 2:06 PM | msn.comWhy Recursion Pharmaceuticals Inc. (RXRX) Performed Worst On Tuesday?March 26 at 9:04 AM | msn.comCathie Wood’s ARK Investment buys 205K shares of Recursion Pharmaceuticals todayMarch 26 at 4:03 AM | markets.businessinsider.comCathie Wood’s ARK Investment buys 161K shares of Recursion Pharmaceuticals todayMarch 21, 2025 | markets.businessinsider.comRecursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Shares Purchased by Charles Schwab Investment Management Inc.March 21, 2025 | marketbeat.comWhy Recursion Pharmaceuticals (RXRX) Dipped More Than Broader Market TodayMarch 20, 2025 | zacks.comPrivium Fund Management B.V. Purchases 41,000 Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)March 20, 2025 | marketbeat.comPlatinum Investment Management Ltd. Acquires 546,929 Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)March 20, 2025 | marketbeat.comRecursion Pharmaceuticals (NASDAQ:RXRX) Shares Gap Down - Here's WhyMarch 19, 2025 | marketbeat.comRecursion appoints Namandje Bumpus, Elaine Sun to boardMarch 18, 2025 | markets.businessinsider.comRecursion Pharmaceuticals (NasdaqGS:RXRX) Jumps 12% Following US$500M Equity OfferingMarch 18, 2025 | finance.yahoo.comRecursion Pharmaceuticals (NASDAQ:RXRX) Stock Price Up 4.5% - What's Next?March 18, 2025 | marketbeat.comWhy Recursion Pharmaceuticals (RXRX) Went Up on Monday?March 18, 2025 | insidermonkey.comRecursion Pharma Down 37% in a Month: Buy, Sell or Hold the Stock?March 18, 2025 | zacks.comRecursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Shares Sold by Nikko Asset Management Americas Inc.March 18, 2025 | marketbeat.comWhich Is a Better Investment, Recursion Pharmaceuticals, Inc. or Zai Lab Limited Stock?March 17, 2025 | aaii.com6RXRX : Recursion Pharmaceuticals's Options: A Look at...March 17, 2025 | benzinga.comBank of New York Mellon Corp Has $5.75 Million Holdings in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)March 17, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeRXRX Company DescriptionsRecursion Pharmaceuticals NASDAQ:RXRX$5.81 -0.16 (-2.68%) Closing price 03/28/2025 04:00 PM EasternExtended Trading$5.78 -0.03 (-0.60%) As of 03/28/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas JPMorgan: The 'NVIDIA of Banking' Poised for More Gains? Why Dollar Tree’s Family Dollar Sale Could Spark a Comeback Joby Aviation Stock: Analyst Confidence and Smart Money Align Ibotta Stock: Why the Buyback Looks Like a Bullish Bet Archer Aviation Stock Sees Surge in Institutional Buys How Can Tomahawk 6 Contribute to Broadcom's AI Growth Story? Microsoft’s Big Malaysia Bet Could Pay Off for Investors Intuitive Machines Gains After Earnings Beat, NASA Missions Ahead Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
